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Abstract
One therapeutic approach to Duchenne Muscular Dystrophy (DMD) recently entering clinical trials aims to convert DMD
phenotypes to that of a milder disease variant, Becker Muscular Dystrophy (BMD), by employing antisense oligonucleotides
(AONs) targeting splice sites, to induce exon skipping and restore partial dystrophin function. In order to search for small
molecule and genetic modulators of AON-dependent and independent exon skipping, we screened ,10,000 known small
molecule drugs, .17,000 cDNA clones, and .2,000 kinase- targeted siRNAs against a 5.6 kb luciferase minigene construct,
encompassing exon 71 to exon 73 of human dystrophin. As a result, we identified several enhancers of exon skipping, acting
on both the reporter construct as well as endogenous dystrophin in mdx cells. Multiple mechanisms of action were
identified, including histone deacetylase inhibition, tubulin modulation and pre-mRNA processing. Among others, the
nucleolar protein NOL8 and staufen RNA binding protein homolog 2 (Stau2) were found to induce endogenous exon
skipping in mdx cells in an AON-dependent fashion. An unexpected but recurrent theme observed in our screening efforts
was the apparent link between the inhibition of cell cycle progression and the induction of exon skipping.
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Introduction
Duchenne Muscular Dystrophy (DMD) is the most common of
nine categories of muscular dystrophy, occurring at an incidence
of 1/3500 live born males [1]. All cases of DMD are caused by a
loss of dystrophin protein expression, however the underlying
genetic mutations for the disease vary greatly between individuals
and can include deletions, insertions or point mutations through-
out the dystrophin gene (DMD), which is the largest gene in the
human genome (spanning 2.4 Mb of the X chromosome) [2,3].
The severity of muscle wasting in DMD means that most patients
die in the second decade of their lives due to respiratory and
cardiac failure, as a consequence of loss of dystrophin expression in
both cardiac and skeletal muscle [4].
Existing DMD therapies are limited to symptomatic treatments
such as glucocorticoids, which decrease inflammation resulting
from muscle cell necrosis and degeneration [5], and improve
muscle strength in DMD patients and tissue engineered from mdx
mice (carrying a spontaneous point mutation in Dystrophin) [6], via
as yet unknown mechanisms. While lifespan and quality of life can
be slightly improved through these treatments [7], the underlying
genetic defect remains. Small molecules that may prove beneficial
to DMD patients include histone deacetylase (HDAC) inhibitors.
Treatment with Trichostatin A (TSA) can improve morphology
and function of skeletal muscle in mdx mice via the upregulation of
follistatin [8], and valproic acid can improve muscle integrity and
function in the mdx/Utrophin
2/2 double mutant mouse model of
DMD via activation of the Akt pathway [9], however these
compounds are yet to be tested in humans. A small molecule
showing potential for treating a subset of DMD patients with
nonsense mutations is PTC124. Efficacy studies in humans are
currently ongoing, following successful studies in the mdx mouse
[10], and safety and tolerability in a phase I trial [11].
One therapeutic approach currently pursued in the clinic that
could treat up to 83% of all DMD cases [12] attempts to convert
DMD to BMD phenotypes. BMD is a milder and rarer form of
muscular dystrophy (,1/20,000) [13] caused by mutations in
dystrophin that enable the production of partially functional
truncated protein products [14,15]. AONs can be designed against
splice sites or enhancer elements to induce exon skipping in cells of
DMD patients, and have shown restoration of the reading frame of
dystrophin 28 days after intramuscular injection of AON into the
tibialis anterior muscle [16]. Further clinical trials are underway to
test different AON chemistries and specific sequences targeting
exon 51, as this AON alone could treat 13% of DMD patients
[12,17]. Studies have shown that as little as 29% of normal levels
of dystrophin protein can alleviate symptoms of muscle weakness
[18], however there has been limited success of restoration of
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istration of AONs in the mdx mouse [19,20], unless given every
other day, over several days or weeks [21,22]. Regular
intramuscular or intravenous injection is cumbersome and is yet
to be tested in DMD patients for its impact on muscle tissue
integrity. An additional disadvantage to AON-based therapy of
DMD is the need to personalize AON sequences depending upon
the patient’s specific dystrophin mutation.
Given the limitations of existing and experimental treatments,
there remains an unmet clinical need for the development of small
molecule therapeutics for DMD. Moreover, there is evidence for
the existence of endogenous mechanisms enabling exon skipping
within DMD transcripts that contain nonsense [23–25] or
frameshift mutations [26]. This highlights an opportunity to
identify novel therapeutic targets for the treatment of DMD and
other genetic diseases. In this study we aimed to identify small
molecule and genetic enhancers of AON-dependent and indepen-
dent exon skipping through the screening of small molecule
libraries with annotated functions, in addition to cDNA and
siRNA collections. Besides several expected mechanisms of action,
and a number of new genetic modifiers including NOL8 and
Stau2, these screens revealed an unexpected connection between
the inhibition of cell cycle progression and enhancement of DMD
exon skipping. This general trend hints at a potentially novel
mechanism of action for HDAC inhibitors in DMD treatment.
Results
DMD Minigene Construct Features Spontaneous Exon
Skipping
The large size of the DMD gene (79 exons spanning 2.4 Mb),
limits the ease of generating genomic overexpression constructs.
However, since splicing can involve enhancer and repressor
sequences within introns [27–29], and pre-mRNA secondary
structures within introns can influence exon recognition [30,31],
we decided to generate luciferase reporter gene constructs
spanning three exons with full-length intervening intronic
sequences to enable protein-protein interactions of all necessary
splicing factors (Figure 1A). Two genomic fragments of human
DMD were selected for generation of luciferase reporter gene
constructs based upon three characteristics: 1) their ability to be
cloned by conventional means (,20 kb in size), 2) the generation
of an in-frame transcript as a result of exon skipping and 3) a
report of patients carrying stop codon mutations within the central
exons (to allow for the generation of minigene constructs with low
basal activity and which mimic mutations documented in the
Leiden DMD mutation database) [32].
Two resulting minigene constructs spanned the 59 end of exon
71 to the 39 end of exon 73 (hE72-Luc) and the 59 end of exon 39
to the 39 end of exon 41 (hE40-Luc). Although these constructs did
not encompass the mutation hotspot regions between exons 2–20
or 45–53, truncation mutations 59 of exon 74 are known to
invariably cause DMD [33,34]. This observation is probably a
result of nonsense-mediated decay of transcripts or a lack of
functional actin or b-dystroglycan domains in the resulting protein
[32]. Reports have been made of spontaneous exon skipping for
some DMD and BMD patients with stop codon mutations
[24,25,35], including within exon 72 [23]. When we transiently
transfected HEK 293 cells with either hE72-Luc(TGA) or hE40-
Luc(TAG) construct this phenomenon could be reproduced in vitro
and detected by RT-PCR (Figure 1B–C). Sequencing and
quantification of relative densities of RT-PCR products confirmed
significant enhancement of skipping of exon 72 in the presence of a
stop codon mutation (45.1% of transcripts from the hE72-
Luc(TGA) construct versus 16.5% of transcripts generated from
hE72-Luc(WT)). Similar results were seen with hE72-Luc(TAG)
and hE72-Luc(TAA) constructs (data not shown). In contrast,
introduction of a stop codon mutation only minimally increased
exon skipping of the hE40-Luc construct (26% of transcripts from
hE40-Luc(TAG) versus 24.6% of transcripts from hE40-Luc(WT),
indicating that sequence specific splicing factors may be involved.
Together these results validated the two DMD minigene
constructs, in that they could mimic the phenomena of
endogenous exon skipping reported in DMD patients with stop
codon mutations, and that they could be used to identify small
molecule and genetic regulators of these endogenous processes
without having to artificially induce the process with high levels of
AON.
Transient transfection of minigene constructs in HEK 293 cells
was used for genomic and small molecule compound high-
throughput screens (HTS) described below, due to superior
luciferase signal when compared to stable clones in either HEK
Figure 1. Splice forms and spontaneous exon skipping of DMD minigene reporter constructs in HEK 293 cells. (A) Schematic of DMD
minigene luciferase reporter gene constructs. A genomic segment of human or mouse DMD containing three exons (a, b, and c) and their intervening
introns (solid lines) was cloned downstream of the SV40 promoter and in-frame with the luciferase coding sequence of the pGL3 vector. Dotted lines
represent splicing of full-length transcript and dashed lines that of the exon skip transcript. Variations of each construct were made containing stop
codon mutations in exon b, as indicated by TGA. (B) RT-PCR products with primers spanning DMD exon 71 to luciferase (marked + or 2 for with and
without reverse transcriptase enzyme) from untransfected HEK 293 cells or cells transfected with the hE72-Luc construct with (tga) or without (wt) a
TGA stop codon mutation, showing spontaneous exon skipping that is enhanced upon addition of a nonsense mutation. (C) RT-PCR products with
primers spanning DMD exon E39 to luciferase from untransfected HEK 293 cells or cells transfected with the hE40-Luc construct with (tag) or without
(wt) a TAG stop codon mutation show the same effect, although less dramatic.
doi:10.1371/journal.pone.0008348.g001
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293 cells was not expected to limit the hits obtained from our
screens, given that spontaneous exon skipping of minigene
constructs could occur in this cell line, and that an analogous
screen monitoring splicing of a microtubule-associated protein tau
(MAPT) construct was recently performed in HEK 293 cells and
identified drugs capable of functioning on endogenous MAPT in
SHSY-5Y neuroblastoma cells [36]. Reporter gene assay condi-
tions were further optimized by testing the concentration of AON
and identifying a positive control reference compound.
Validation of DMD Reporter Gene Assay
hE72-Luc(TGA) was chosen for HTS as it offered a 10 times
higher baseline luciferase signal than hE40-Luc constructs
(presumed to be due to higher rate of spontaneous exon skipping
of hE72-Luc(TGA)), allowing for a more robust assay, while still
giving relatively low luciferase expression prior to AON or
compound treatment (RLU ,20% of saturation point of detection
system). Additional reporter gene constructs hE40-Luc(WT) and
mE23-Luc(TAA) (mimicking the mdx mutation in exon 23 of
mouse Dmd) were used to probe for sequence-specificity of
reconfirmed screen hits. Given the evidence that HDAC inhibitors
can enhance both general transcription and specific splicing of
genes such as survival of motor neuron 2 (SMN2) [37] and cystic fibrosis
transmembrane conductance regulator (CFTR) [38], we tested a panel of
compounds of this class against hE72-Luc(TGA) (data not shown).
TSA was found to give the greatest signal increase and was
therefore chosen as a positive control for the small molecule
screen. Since we wished to identify both AON-dependent and
independent genes and small molecule compounds, we titrated a
validated 29O-Methyl AON specific to DMD exon 72 (hE72 AON)
[39]. By analyzing a titration matrix of AON and TSA (Figure 2A)
a limiting dose of 0.5 mM hE72 AON was chosen for all further
experiments, to allow for basal luciferase expression and detection
of small molecule and genetic enhancers of AON-induced exon
skipping, in addition to AON-independent regulators. The hE72-
Luc reporter gene assay was further validated by qPCR. Primer-
probe sets were designed to amplify transcripts containing human
exon 71-exon 73 (exon skip) and exon 72-exon 73 (full-length)
DMD splice junctions. Data from each primer-probe set was
Figure 2. TSA enhances AON-induced exon skipping of hE72-Luc DMD minigene reporter construct in HEK 293 cells. (A) HEK 293 cells
were transiently transfected with hE72-Luc and 0–1 mM hE72 AON 24 h prior to addition of 0–1 mM TSA in 1536-well format. Luciferase activity
(RLU=relative luciferase units) was measured 24 h after compound addition (48 h post-transfection) and shows a positive trend with AON
concentration that is enhanced with TSA treatment. Inhibition of signal begins to occur at 1 mM AON (black squares). Data points are an average of 6
replicates and error bars represent standard deviation. (B) HEK 293 cells were transiently transfected with hE72-Luc and 0–1 mM hE72 AON 6 h prior
to addition of 0–10 mM TSA in 24-well format prior to qPCR analysis of transcripts 24 h after compound treatment. An increase in the ratio of exon
skip (SK) to full-length (FL) transcripts in seen with increasing AON concentration that is enhanced with TSA treatment, indicating it is not a general
increase in transcriptional activity. Data points are an average of 5 replicates and error bars represent standard deviation.
doi:10.1371/journal.pone.0008348.g002
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for each sample and results then expressed as the fold change in
the ratio of normalized skip/full-length transcript levels
(Figure 2B). At each dose of hE72 AON tested, TSA was seen
to give an additional increase in exon skip transcript levels,
indicating that it was not simply enhancing transcriptional activity
in general in the context of the hE72-Luc reporter. Thus the
qPCR assay highlights two separate mechanisms for TSA to
enhance the luciferase signal of the DMD minigene construct –
one as a general effecter of gene transcription by modulating
chromatin structure, and another as a modulator of pre-mRNA
splicing. Given its large assay window and mechanistic relevance,
1 mM TSA was used as a positive control during the small
molecule screen.
Tubulin Modulators and HDAC Inhibitors Enriched in
Known Drug Hit List
A collection of ,10,000 ‘‘known drug’’ small molecule
compounds with functional annotation derived from public
databases including PubChem and the World Drug Index
(WDI) [40], was screened at a single dose of 8.3 mM (0.83%
DMSO) in 1536-well format against HEK 293 cells transiently
transfected with the hE72-Luc(TGA) construct and 0.5 mM hE72
AON. This screen yielded a Z’=0.6, indicating a robust assay
amenable to HTS. The concentration of compound used was the
highest dose possible in 1536-well format, since DMSO concen-
trations above 1% resulted in cellular toxicity (data not shown).
From this screen 70 compounds gave $2 fold increase in luciferase
signal above plate mean values in duplicate (0.70% hit rate) and 66
of these showed a dose-response. From this hit list 37 unique
compounds (several structures were represented more than once
due to duplication in the library screened) showing sigmoidal dose-
response curves were chosen for re-testing from purified powders
(.85% purity by LC-MS) in 384-well format, allowing for dosing
up to 100 mM. 21/37 compounds reconfirmed from powder, in
addition to the positive control TSA. The two most common
classes of compound identified from this small molecule screen
were tubulin modulators and HDAC inhibitors (Table 1), the most
potent being apopicropodophyllin-beta and podophyllotoxin,
cyclolignans known to inhibit microtubule assembly [41].
Although the majority of reconfirmed compounds significantly
increased the mitotic index of HEK 293 cells and showed toxicity
at equivalent or lower concentrations than the EC50 in hE72-Luc
reporter gene assay, qPCR analysis demonstrated that 17/21 of
the compounds specifically enhanced exon skipping in the context
of the hE72-Luc reporter construct. Those compounds giving a
skip/full-length transcript ratio of .2 after normalization to
DMSO treated cells were regarded as specific enhancers of exon
skipping.
Next we wished to test whether the 21 reconfirmed hit
compounds had the ability to modulate exon skipping of
endogenous Dmd transcripts in mdx cells. While the expression
of DMD protein significantly increases upon in vitro differentiation
of healthy muscle cells into multinucleated myotubes [42], the
variable nature of differentiation within and between experiments
made study in myotubes infeasible for medium-throughput dose-
response studies. Concurrent qPCR studies of DMSO-treated
mdx myoblasts and myotubes showed that full-length Dmd
transcript levels were not significantly different pre- and post-
differentiation for 3 days (P=0.2, student’s two-tailed t-test), and
more reproducible results were obtained from myoblasts (than
myotubes) upon treatment with increasing concentrations of AON
and TSA controls, so all further studies were conducted in mdx
myoblasts. qPCR showed that 16 of the reconfirmed compounds
also induced exon skipping of endogenous mouse Dmd exon 23 in
mdx cells in the absence of mE23 AON (skip/full-length ratio .2
using primer-probes specific to exon 22–24 and exon 22–23 splice
junctions). In mdx cells only 8/16 of these compounds induced
exon skipping at higher levels than 0.2 mM mE23 AON alone.
This is in part due to the high potency of the AON (0.2 mM mE23
AON induces 200–600% increase in ratio of skip/full-length Dmd
transcripts compared to DMSO treatment alone), and near zero
levels of endogenous exon 23 exon skip transcripts present in mdx
cells [43,44]. Together this data hints at a possible connection
between cell cycle inhibition (most commonly through mitotic
arrest) and exon skipping in exogenous and endogenous DMD
transcripts.
Exon Skipping Activity Correlates with Mitotic Index
To further test the observation that the ability of a small
molecule to induce exon skipping is related to its ability to arrest
cells in mitosis, we utilized C2C12 cells stably expressing a human
DMD minigene construct where treatment with an AON specific
to exon 50 triggers splicing out (skipping) of exon 50 from within
the coding region of EGFP, thereby restoring its reading frame
and increasing GFP signal. Hence the C2C12 hE50-GFP cells
enabled monitoring of both exon skipping (GFP) and mitotic index
status (propidium iodide staining) in the same sample following
compound treatment. Reconfirmed purified compounds of each
class were tested in 8 point, 3-fold dilutions in C2C12 hE50-GFP
cells transfected with 0.5 mM hE50 AON. Interestingly, a positive
relationship was observed between exon skipping (%GFP positive
cells) and mitotic index for the tubulin modulators colchicine and
fenbendazole, as well as the flavoenzyme inhibitor diphenyleneio-
donium and a steroid hormone receptor modulator (Figure 3).
Clearly lacking such a trend in activities were the HDAC
inhibitors TSA, scriptaid and dinaline (data not shown). This
indicates at least two independent mechanisms of action for the
small molecule hits, one that is cell cycle-dependent and another
that is not.
Similar Mechanisms of Action Identified from cDNA and
Small Molecule Screens
In order to better understand the molecular mechanisms
involved in exon skipping we performed a genome-wide cDNA
overexpression screen. Given the known involvement of serine/
arginine-rich (SR) proteins in alternative splicing [45] we first
tested a panel of 29 different Origene and MGC cDNA clones
encoding SR proteins in co-transfection experiments with hE72-
Luc +/2AON. All SR proteins tested induced at least a 2 fold
increase in luciferase signal relative to reporter construct alone
(data not shown), and were tested in parallel with other clones that
did not show such an effect. The best assay window was seen with
overexpression of human splicing factor, arginine/serine-rich 1
(SFRS1) (BC033785 in pCMV-SPORT6) or human splicing
factor, arginine/serine-rich 16 (SFRS16) (NM_007056.1 in
pCMV6-XL5), so these were chosen as positive controls
(Figure 4A) in the following screen. Both SFRS1 and SFRS16
gave increased luciferase signals in the presence or absence of
hE72 AON, however, a slight synergy of AON and SR protein
overexpression was observed (4 fold increase above baseline
without AON and 6 fold in the presence of AON).
A collection of ,17,000 MGC cDNA clones were screened in
384-well format against HEK 293 cells co-transfected with the
hE72-Luc(TGA) construct and 0.5 mM hE72 AON. From this
screen 143 clones reconfirmed in triplicate (hit rate of 0.83%) by
giving $2 fold increase in luciferase signal over the plate mean
(Table S1). Reconfirmed hits were categorized according to the
DMD Exon Skipping Modulators
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annotated), and as expected for any reporter gene assay,
transcription factors were the most common functional group
(Figure 4B). Hits with known functional relationships to exon
skipping included genes involved in RNA stability or processing
(such as Sfrs3 and Rbm3, 4 and 5). Other common gene functions
included DNA and chromatin modification, such as histones and
the ATP-dependent DNA helicase RecQ5 protein-like 5
(RECQL5). Unexpectedly, but in keeping with the small molecule
screening data, clones encoding cell cycle-regulating kinases such
as cyclin-dependent kinase 8 (CDK8) and CHK2 checkpoint
homolog (Chek2) appeared on the cDNA hit list, together with
clones encoding regulators of cytoskeleton remodeling such as
tubulin polymerization-promoting protein family member 2
(TPPP2) and Sfi1 homolog, spindle assembly associated (SFI1).
In order to highlight the cDNA clones whose overexpression may
be directly involved in pre-mRNA processing and exon skipping,
we carried out a network analysis using all 135 confirmed human
genes (or orthologues of mouse genes) in the database. Considering
all interaction pairs among proteins encoded by our confirmed
genes, including those proteins known to be associated with RNA
based on literature, we obtained a network consisting of 81
proteins and 137 interactions (p,0.001) (Figure 4C), from which
we also identified a densely-connected sub-network (Figure 4D).
The larger network was found to contain a 23-fold enrichment in
components of the 17S U2 snRNP complex (key for splice site
selection [46]), 20-fold enrichment in ubiquitin-conjugating
enzymes, and 5 to 6-fold enrichment in regulators of cell size
and growth (p,0.001), based upon the Gene Ontology (GO)
annotation database. The sub-network was more specifically
enriched for proteins involved in mRNA splicing and processing
and nucleic acid metabolism (proteins in each network are detailed
in Table S2). The identification of specific mRNA splicing
networks further validated the minigene reporter approach used
in this study, and the presence of ubiquitin-conjugating enzymes is
in agreement with reports that the ubiquitin pathway is a means of
degrading specific splicing factors to promote alternative splicing
events [47].
Table 1. Small molecule compounds with reconfirmed activity in hE72-Luc assay
[a], their known functions, cell cycle stage of
action, activity and potency in hE72-Luc, HCI mitotic index and Alamar blue toxicity assays in HEK cells, as well as exon skipping
activity on the hE72-Luc construct in HEK cells and on endogenous mouse Dystrophin transcripts in mdx cells, as determined by
qPCR.
Common name Known Function
Cell Cycle
Stage of
Action
hE72Luc+
AON
Median
FC
[b]
hE72Luc+
AON
Potency
(EC50 in
mM)
hE72+
AON
qPCR
[c]
mdx+
AON
qPCR
[d]
mdx
qPCR
[e]
Mitotic
Index
Median
FC
Mitotic
Index
Potency
(EC50 in
mM)
Toxicity
(IC50 in
mM)
Apopicropodophyllin-beta Tubulin modulator G2/M [41] 3 0.03 22.86 ,2 3.56 14 0.02 0.04
Colchicine Tubulin modulator G2/M [92] 2 1.5 27.83 ,2 3.66 8 0.05 0.2
Demecolcine Tubulin modulator G2/M [92] 3 1 9.59 ,2 ,2 11 0.0004 0.001
Fenbendazole Tubulin modulator G2/M [93] 3 2.2 2.76 2.21 ,2 6 0.1 0.4
Mebendazole Tubulin modulator G2/M [93] 4 4.5 3.87 2.17 ,2 10 0.3 0.3
Nocodazole Tubulin modulator G2/M [94] 8 0.94 12.49 ,2 ,2 7 0.02 0.02
Oxibendazole Tubulin modulator G2/M [95] 3 3.2 3.45 ,2 3.29 9 0.2 0.2
Podophyllotoxin Tubulin modulator G2/M [41] 5 0.16 21.09 ,2 ,2 11 0.0003 0.0003
Tn-16 Tubulin modulator G2/M [96] 18 6.1 7.55 2.83 2.57 12 0.2 0.06
Tubulazole Tubulin modulator G2/M [97] 10 1.2 25.88 ,2 6.93 8 0.05 0.07
Tubulin polymerization
inhibitor
Tubulin modulator G2/M [97] 3 0.96 4.13 3.09 6.92 5 4.7 10
Dinaline HDAC Inhibitor G1 [98] 56 10 3.20 2.18 3.68 ,2N A
[g] 12
Nicotinamide analog HDAC Inhibitor ND
[f] 4 65 9.98 ,2 4.90 15 0.7 0.1
Scriptaid HDAC Inhibitor G1+G2/M [99] 47 0.54 16.79 ,2 4.95 2 0.8 2.7
Trichostatin A HDAC Inhibitor G1+G2 [100] 17 0.16 45.51 ,2 4.03 ,2N A
[g] 0.3
Doxifluridine DNA intercalator S [101] 4 6.2 5.53 17.01 3.12 ,2N A
[g] 0.03
Hoechst DNA intercalator S [102] 32 1.3 31.79 ,2 2.43 ,2N A
[g] 2.5
Luteolin Flavonoid G1 [103] 3 6.5 ,2 3.11 4.21 ,2N A
[g] 80
Pin1 modulator Kinase inhibitor G2/M [104] 3 3.3 3.97 2.30 2.77 11 0.3 0.5
Steroid receptor modulator Receptor modulator ND
[f] 99 . 3,2 2.43 2.49 6 3 8
Parthenolide Anti-inflammatory G2/M [105] 11 10 ,2 2.08 2.87 3 1.5 10
Diphenyleneiodonium Flavoenzyme inhibitor G1+G2/M
[106,107]
38 . 5,2 10.02 ,2 ,2N A
[g] 1
[a] Compound classed as reconfirmed hit when luciferase activity of purified powder was .2 fold above DMSO in duplicate plates; [b] FC=fold change above DMSO; [c]
assay was performed in the presence of 0.5 mM AON and 1 mM compound in HEK cells transfected with hE72-Luc and data represents average fold change in the
normalized skip/full-length ratio; [d] assay was performed in the absence of AON and presence of 1 mM compound in mdx-H2K cells and data represents average fold
change in the normalized skip/full-length ratio; [e] assay was performed in the presence of 0.2 mM AON and presence of 1 mM compound in mdx-H2K cells and data
represents average fold change in the normalized skip/full-length ratio; [f] not determined; [g] not applicable.
doi:10.1371/journal.pone.0008348.t001
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annotated as encoding general transcription factors (including 9
RNA binding proteins) were selected for further sequence
specificity and mechanism of action studies. Genes inducing
skip/full-length ratios of .2 after normalization to mock
transfected cells in the hE72-Luc qPCR assay (33/45 clones) were
regarded as selective enhancers of exon skipping (Table 2). Twenty
six of these cDNAs acted in an AON-independent fashion. Genes
such as epsin 3 (Epn3), nucleolar protein 8 (NOL8) and RNA
binding motif protein 5 (Rbm5) reproducibly induced a higher fold
change above baseline in the absence than in the presence of
AON. For two of these clones (NOL8 and Rbm5) the same trend
was observed in the hE72-Luc luciferase assay. The same 33
clones showing exon skipping enhancement on the hE72-Luc
construct were tested for sequence specificity against the hE40-Luc
construct. Very few clones enhanced luciferase signal of hE40-Luc,
and those that did were generally strong hits in the hE72-Luc
assay. Examples of such clones are those encoding RNA binding
proteins RBM4 and Rbm5, which are known to alter splicing of
genes such as tau [48] and alpha-tropomyosin [49], or caspase 2
[50] and Fas [51], respectively. RBM5 was identified as a member
of the protein-protein interaction sub-network described above, as
it is one of the better described RNA binding proteins.
Next, the effects of cDNA hits on endogenous mouse Dmd
splicing were tested in mdx cells (Table 2). Due to the extremely
low level of spontaneous Dmd exon skipping in mdx cells, only
epsin 3 was found to induce a skip/full-length ratio .2 in the
absence of AON, while several additional clones showed a weaker
activity and skipping ratios .1. Higher levels of splice products
could be seen after co-transfection of 0.2 mM AON, and under
these conditions overexpression of 8 cDNAs gave a skip/full-length
transcript ratio .2. Two of the strongest exon skipping enhancers
in the mdx cells of potential therapeutic interest were the nucleolar
protein NOL8 and staufen RNA binding protein homolog 2
(Stau2). Both genes code for RNA binding proteins of poorly
characterized function, hence they were not identified by data
mining of protein-protein interaction databases. NOL8 interacts
with at least one DEAD-box RNA helicase DDX47 [52]. Stau2
has a MAPK docking site that is involved in dendritic mRNA
transport in neurons [53,54], and although its function in skeletal
muscle is not yet understood, it localizes to the neuromuscular
junction, and protein expression levels are increased during
myogenic differentiation [55].
Kinase siRNA Screen Confirms Cell Cycle Regulation of
DMD Exon Skipping
In order to gain further insight into the mechanism of DMD
exon skipping, and potentially identify novel targets for drug
development, we performed a kinase targeted siRNA screen (4
siRNAs per target for 544 kinases). This screen was performed in
384-well format against HEK 293 cells bulk transfected with the
hE72-Luc(TGA) construct in the presence of 0.5 mM hE72 AON,
6 hr prior to siRNA transfection. Since several cell cycle regulators
were reconfirmed as hits from our small molecule and cDNA
screens, we sought to validate siRNAs targeting tubulin and polo-
like kinase 1 (PLK1) as our positive controls. 72 h knockdown of
tubulin expression resulted in a 3–4 fold increase in luciferase
signal (slightly higher in the presence of AON) and knockdown of
PLK1 caused a ,2.5 fold increase (no additional enhancement in
the presence of AON) (Figure 5A). Transfection efficiency was
monitored by use of the pGL3 siRNA targeting luciferase and was
found to be consistent throughout the screen (data not shown). A
hit list of 55 target genes was generated based upon siRNAs that
gave $2 fold increase in luciferase signal across duplicate plates
(Table S3) and these hits were categorized based upon known or
predicted functions (Figure 5B). A third of kinase targets with
known function are involved in regulation of cell cycle, such as
never in mitosis gene a-related kinases (NEKs) and cyclin-
Figure 3. Small molecule enhancers of exon skipping also increase the mitotic index of hE50-GFP C2C12 cells. A positive relationship
between mitotic arrest and exon skipping was observed for a subset of small molecule hits in hE50-GFP C2C12 cells transfected with 0.5 mM hE50
AON, and 6 h later treated with 0–10 mM compound. Cells were fixed and analyzed by FACS 24 h after compound addition for exon skipping (%GFP+
cells) and mitotic index (%G2/M cells).
doi:10.1371/journal.pone.0008348.g003
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PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8348Figure 4. Enhancers of DMD exon skipping identified by genome-wide cDNA screening. (A) Luciferase activity (RLU) of hE72-Luc in HEK
cells +/2AON and SR protein cDNA positive control constructs 48 h post-transfection. (B) Reconfirmed cDNA hits classified according to known or
proposed function. (C) Network cluster diagram of direct protein-protein interactions of reconfirmed cDNA hits (pink) including those with known RNA
binding activity(green).RNAbinding proteinsencodedbyhits were EXOSC9,LOC653232,MRPL51,NOLA1, RBM3,RBM5,RPL15, RPL36AL,RPS27A, RPS3,
SFRS1, SFRS16, and SFRS3. (D) Sub-network of direct protein-protein interactions at the core of the complex represented in (C), including known RNA
binding proteins NOLA1, RBM5, RPL36AL, SFRS1 and SFRS3 (green), and 12 other cDNA hits (pink). See Table S2 for protein details.
doi:10.1371/journal.pone.0008348.g004
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recently linked to breast cancer susceptibility [56] gave the largest
increase in luciferase signal (15 fold above plate mean). As was
observed from the small molecule and cDNA screens, this data
confirmed the previously observed functional connection between
mitotic arrest and enhanced DMD exon skipping.
Discussion
We have used an unbiased screening approach to identify small
molecule and genetic regulators of AON-induced exon skipping of
Dystrophin. Specific enhancement of the ratio of exon skip/full-length
transcripts was determined by qPCR analysis, eliminating hits that
Table 2. cDNA clones with reconfirmed activity in hE72-Luc assay
[a] and specific enhancing effects on exon skipping of the hE72-
Luc construct in HEK cells, together with their effects on splicing of endogenous mouse Dystrophin transcripts in mdx cells, as
determined by qPCR.
Symbol Gene Name
Genbank
Accession
hE72-
Luc+AON
[b]
hE72-
Luc
[c]
hE40-
Luc+AON
[b]
hE40-
Luc
[c]
hE72+AON
qPCR
[b]
hE72
qPCR
[c]
mdx+AON
qPCR
[d]
mdx
qPCR
[e]
Adck2 AarF domain containing kinase 2 BC069944 8.13 3.74 0.45 0.56 2.09 0.68 1.02 0.53
Atp13a1 ATPase type 13A1 BC138722 7.33 3.92 0.33 0.31 3.82 3.57 1.62 1.75
CAPNS1 Calpain, small subunit 1 BC064998 16.27 4.31 0.60 0.46 2.56 2.11 1.15 0.52
Cdc42ep1 CDC42 effector protein 1 BC083130 11.30 5.24 0.47 0.39 9.89 1.65 1.14 0.81
Chek2 CHK2 checkpoint homolog BC056617 11.33 6.90 1.44 0.92 2.67 1.90 1.16 0.79
Dnmt3a DNA methyltransferase 3A, variant 1 BC007466 6.86 2.55 0.87 2.80 4.64 7.56 2.04 1.17
Cdcp1 CUB domain containing protein 1 BC085253 15.17 4.00 0.38 0.31 3.89 3.54 3.12 1.21
Epn3 Epsin 3 BC016454 5.05 2.70 0.26 1.08 2.81 6.87 1.58 2.11
Fgf5 Fibroblast growth factor 5 BC071227 15.74 15.53 0.58 0.78 3.25 1.66 2.24 0.54
GPATC2 G patch domain containing 2 BC042193 7.06 4.59 0.40 1.70 2.40 3.56 2.32 1.46
Gpr39 G protein-coupled receptor 39 BC085285 5.67 3.27 0.30 0.27 2.61 3.42 1.45 0.34
H3f3a H3 histone, family 3A BC002268 8.51 6.04 0.58 2.23 5.48 4.68 2.83 1.40
H3F3A H3 histone, family 3A BC081561 18.44 18.81 1.63 1.42 3.00 2.45 1.75 1.42
HIST1H4I Histone cluster 1, H4i NM_003495 24.47 16.67 1.27 1.01 3.67 1.76 2.87 1.28
Ing1l Inhibitor of growth family, member 1-like BC096433 8.65 5.53 1.10 0.79 6.39 3.63 9.06 0.46
Ing4 Inhibitor of growth family, member 4 BC009127 8.04 2.70 1.72 3.79 2.20 2.42 1.59 1.11
EEPD1 Endonuclease/exonuclease/phosphatase
family domain containing 1
BC065518 9.58 4.37 0.32 0.34 3.12 2.18 1.29 0.62
Mdn1 Midasin homolog BC071242 17.70 6.61 1.24 0.88 4.70 3.53 2.60 1.00
MORF4L2 Mortality factor 4 like 2 BC056899 12.40 25.72 7.08 4.09 20.09 6.06 1.80 1.13
Morf4l2 Mortality factor 4 like 2 BC088731 20.50 28.68 10.22 9.22 19.96 8.84 2.12 1.32
Nipa2 Non imprinted in Prader-Willi/
Angelman syndrome 2 homolog
BC038499 19.26 8.26 0.75 0.61 2.04 2.58 1.27 0.70
NOL8 Nucleolar protein 8 BC013788 5.05 10.89 0.60 0.45 2.37 4.51 3.11 1.03
RAD1 RAD1 homolog NM_002853 14.38 11.51 0.77 0.51 2.73 4.41 1.71 0.63
RBM4 RNA binding motif protein 4 BC032735 11.34 12.46 6.38 21.99 4.92 8.32 2.17 1.06
Rbm5 RNA binding motif protein 5 BC031899 15.23 25.12 5.48 3.29 3.53 13.88 2.86 0.89
Rpl15 Ribosomal protein L15 BC091735 10.36 10.78 0.51 0.42 4.66 5.11 2.35 1.19
RPS6KB1 Ribosomal protein S6 kinase, polypeptide 1 BC053365 7.11 21.02 1.03 0.62 3.75 2.70 1.61 1.17
Sfrs3 Splicing factor, arginine/serine-rich 3 BC071196 18.33 3.83 0.58 0.49 2.81 1.58 2.62 0.94
SPHK1 Sphingosine kinase 1 BC030553 9.84 7.61 0.45 1.61 3.29 8.19 2.00 1.00
Stau2 Staufen RNA binding protein homolog 2 AF459099 6.59 4.60 0.82 2.12 3.55 5.65 3.26 1.38
Uaca Uveal autoantigen with coiled-coil
domains and ankyrin repeats
BC033470 5.29 2.54 0.32 0.97 2.87 4.58 3.25 1.27
UBE2C Ubiquitin-conjugating enzyme E2C,
variant 1
BC016292 8.35 2.83 0.88 2.42 4.72 7.17 1.91 1.11
Xrcc1 X-ray repair complementing defective
repair in Chinese hamster cells 1
BC085281 28.44 20.26 0.87 0.64 3.06 1.84 1.49 0.53
[a] cDNA clones classed as reconfirmed hits when activity was .2 fold above hE72-Luc alone in an independent experiment to the initial screen; [b] Assay was
performed in the presence of 0.5 mM AON and data represents median fold change for Luciferase assays or average fold change for qPCR; [c] Assay was performed in
the absence of AON and data represents median fold change for Luciferase assays or average fold change in the normalized skip/full-length ratio for qPCR; [d] mdx-H2K
cells were co-transfected with 0.2 mM AON and cDNA clones prior to qPCR analysis and data represents average fold change in the normalized skip/full-length ratio; [e]
mdx-HEK cells were transfected with cDNA clones alone and data represents average fold change in the normalized skip/full-length ratio.
doi:10.1371/journal.pone.0008348.t002
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concern for any HTS using luciferase reporters [57]. Ideally a screen
for modulators of DMD exon skipping would be performed in
myotubes, since the tissue most affected in DMD patients is skeletal
muscle. However, given the variable nature of myoblast differenti-
ation, this was not technically feasible for a robust HTS assay. The
fact that an equivalent number of compounds identified via HTS in
HEK 293 cells showed specific enhancement of AON-induced exon
skipping of endogenous Dmd in the mdx myoblast cellular context as
were observed using the hE72-Luc reporter in HEK 293 cells
indicates that the mechanisms of action involve ubiquitous molecules.
In agreement with our results, Stoilov et al. also found that
compounds identified via HTS with a minigene reporter construct
in HEK 293 cells were capable of specifically enhancing inclusion of
exon 10 in endogenous transcripts of MAPT [36].
The most potent small molecules identified by our DMD exon
skipping screen were podophyllotoxin tubulin modulators, and
HDAC inhibitors TSA and scriptaid. HDAC2 [58], 4 and 5 [59]
have been identified as causative of a higher global deacetylase
activity in mdx mice. In addition, both TSA [8] and valproic acid
[9] HDAC inhibitors improve morphology and function of skeletal
muscle in DMD mouse models - positive effects accredited to the
upregulation of follistatin or Akt signaling pathways, respectively.
Our data suggests an additional role for HDAC inhibitors in the
amelioration of dystrophic phenotype in these studies, that of exon
skipping and restoration of Dystrophin reading frame.
HDAC inhibitors can act therapeutically in other genetic
diseases. TSA increased SMN2 gene expression in a mouse model
of spinal muscular atrophy (SMA), and significantly enhanced
exon 7 inclusion (the splicing defect) in SMN2 transcripts [60]. In
addition, M344 specifically enhanced SMN2 exon 7 inclusion in
primary fibroblasts from SMA patients [37], and was proposed to
act via upregulation of protein expression of the SR-like splicing
factor human transformer 2, beta 1 (Htra2-b1). Sodium butyrate
Figure 5. Repressors of DMD exon skipping identified by kinome siRNA screening. (A) Luciferase activity (RLU=relative luciferase units) of
hE72-Luc in HEK cells +/2AON and PLK1 and tubulin positive control siRNAs 72 h post-transfection. (B) Reconfirmed siRNA hits classified according to
known or proposed function.
doi:10.1371/journal.pone.0008348.g005
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correct reading frame of a point mutation associated with cystic
fibrosis, and restore chloride channel function [38]. Hence HDAC
inhibitors may promote exon inclusion or exclusion (skipping)
depending upon the location and sequence of splicing factor
binding sites present in the flanking regions. This breadth of action
may hinder the usefulness of HDAC inhibitors as therapeutics for
genetic disease. However, if DMD protein expression need only be
29% of normal levels to alleviate symptoms of muscle weakness
[18], a dosing regimen for HDAC inhibitors may be possible that
induces specific exon skipping without substantial off target effects
and toxicity seen at high doses in this and other studies [37].
An unexpected finding of this study was the apparent
connection between cell cycle progression (particularly mitotic
arrest) and exon skipping. Tubulin modulators, cytoskeletal
remodeling proteins, and NEK and CDK kinase knockdown
were found to stimulate exon skipping in our reporter construct as
well as endogenous Dmd pre-mRNA. Traditionally it is believed
that dissolution of the nuclear envelope and condensation of
chromosomes during mitosis inhibits transcription, at least in part,
by displacement of the general transcription factor TFIID [61].
However, a recent finding that minor splicing of U12-class introns
occurs in the cytoplasm [62,63] raises the question of how much
splicing can occur in mitotic cells? Transcriptional profiling of the
cell cycle in human fibroblasts using microarrays identified 227
genes whose expression was enriched during G2/M phase [64].
This data agrees with our finding that DMD exon skipping was
enhanced by induction of mitotic arrest. Cho et al. also found that,
in addition to transcripts regulating cell cycle and chromosome
segregation, transcripts involved in actin-based cytoskeletal
reorganization were up-regulated during G2 phase of the cell
cycle [64]. This may explain our observed trend between
overexpression of cDNA clones involved in cytoskeleton remod-
eling and enhanced exon skipping.
DNA intercalators doxifluridine and hoechst were also recon-
firmed small molecule hits that enhanced the proportion of DMD
exon skip transcripts in mdx cells in this study. Another DNA
intercalator, aclarubicin, was found to enhance SMN2 inclusion of
exon 7 (resulting in increased SMN2 protein levels) in type I SMA
fibroblasts [65]. The mechanism of aclarubicin was proposed to be
alteration of SR protein localization. Similarly, phosphatase
inhibitor sodium vanadate is proposed to enhance exon 7 inclusion
in SMN2 transcripts via regulation of SR protein phosphorylation,
which determines protein sub-localization within the nucleus [66].
Therefore, our surprising finding that induction of mitotic arrest
enhances a cell’s ability to skip exons in DMD may simply be a
consequence of the cell cycle-dependent means of regulating RNA
binding proteins, and in fact concur with our expected finding that
overexpression of RNA binding proteins RBM4, Rbm5 or Sfrs3
promotes DMD exon skipping. SR protein kinase 1 (SRPK1)
contributes to the majority of SR protein phosphorylation, is 3–5
fold more active in metaphase versus interphase [67], and
translocates to the nucleus at the G2/M boundary [68]. In
addition to SRPK protein kinases that regulate SR protein
phosphorylation and redistribution within the nucleus [69],
topoisomerase I can also phosphorylate SR proteins and regulate
splicing [70]. Whether DNA intercalators also bind to SR proteins
to modify their localization, or act by steric hindrance of SR
protein binding to pre-mRNA remains to be determined.
SR proteinsplayan important role intheregulationofalternative
splicing and exon skipping of the DMD gene, as highlighted by a
case ofBMDwhereexon skippingaround a DMD exon27 nonsense
mutation results fromloss ofa purine-richexonicenhancersite [35].
However the variable phenotypes observed in a family carrying the
same nonsense mutation in DMD exon 29 (asymptomatic to severe
BMD with cardiomyopathy), and partial protein product produced
by skipping exon 29, suggest that individuals differ in their ability to
activate endogenous exon skipping mechanisms [71]. Such
processes do not just apply to DMD, and are not only induced by
nonsense mutations. Missense mutations in SMN2 are enough to
abrogate splicing factor arginine/serine-rich 1 (SFRS1/SF2/ASF)
binding and promote exon skipping of exon 7 [72] in cases of SMA.
Similarly, in cases of frontotemporal dementia with parkinsonism,
chromosome 17 type (FTDP-17), several missense, silent and
intronic mutations withinsplicing enhancer and silencer elements in
the MAPT gene encoding tau can increase or decrease the extent of
exon 10skippingand hencethe severityof disease duetotau protein
aggregates [73].
Cells maintain a tissue-specific balance of activities of SR
proteins and antagonizing hnRNP proteins that can vary during
development and mitogenic stress, and these proteins require a
specific level of phosphorylation for their activity [74,75]. SR
protein phosphorylation and function can also be regulated by
altering chaperones of SRPK1 [76], suggesting that identification
of additional binding partners of SRPK proteins, or novel tissue-
specific kinases that regulate SR protein activity may prove useful
for future therapeutic strategies targeting exon skipping. It would
be interesting to further investigate DMD pre-mRNA binding sites
of some of our novel cDNA screen hits, such as NOL8 and Stau2,
as well as the better characterized RBM4 and 5 and Sfrs3, to help
understand the process of exon skipping. However, given the
importance of SR and RBM proteins for constitutive and
alternative splicing during Drosophila and mouse development
[77–79], and maintenance of mammalian cell viability [80], it is
unlikely that proteins of these classes hold significant therapeutic
potential for DMD unless delivered directly into muscle tissue.
However, cancers caused by mutations in SR protein binding sites
may benefit from a molecule’s ability to both induce mitotic arrest
and alter alternative splicing, and there is growing evidence to
suggest that altering the balance of SF2/ASF expression regulates
malignant transformation via alternative splicing of Ron tyrosine
kinase receptor and Rac1 GTPase [81].
Here we have used a comprehensive HTS approach utilizing a
DMD minigene reporter construct to identify novel small molecule
and genetic modulators of exon skipping. We confirm previous
reports of the importance of balancing the expression levels of
splicing factors, by identification of RBM and SR proteins from a
genome-wide cDNA screen for regulators of DMD exon skipping.
In addition, we describe the unexpected relationship between exon
skipping and the induction of cell cycle arrest, and propose that
this is mediated by regulation of splicing factor distribution and
function with G2/M entry. This association with cell cycle was
found at the level of small molecule tubulin modulators, siRNAs
targeting NEK and CDK kinases, and cDNA clones regulating
cytoskeleton remodeling. The fact that one of the first descriptions
of HDAC inhibitors’ ability to regulate gene expression via
chromatin remodeling was in regards to p21 gene expression, and
the subsequent arrest of cells in G1 and G2 phases of the cell cycle
[82] also agrees with our finding that small molecules that enhance
exon skipping of endogenous and exogenous Dystrophin arrest cells
in G2 and M phases. It remains to be determined whether HDAC
inhibitors are mediating this effect via regulation of SR proteins, or
by broader means, but our data does suggest a novel mechanism
by which HDAC inhibitors can alleviate symptoms in mdx mice
that has yet to be described. The work presented here is a starting
point for understanding the endogenous mechanisms of exon
skipping within mammalian cells that we hope may contribute to
future therapeutics for DMD and other genetic diseases.
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Construct Cloning
The genomic segment spanning exon 71 to exon 73 of human
DMD was amplified by PCR using NEB Phusion polymerase and
200 ng male genomic DNA as template (Promega), generating a
5.6 kb product with NcoI restriction sites at both ends (forward:
59TTGCACCATGGTTACTCTGATCAACTTCTG
39 and re-
verse:
59GGATACCATGGTGCTCTCATTAGGAGAGATG
39).
This fragment was cloned into the NcoI site immediately upstream
of luciferase in the pGL3 promoter vector (Promega), and the
ATG start codon of luciferase was mutated to TTG via single
primer mutagenesis [83]. Correct orientation and reading frame
were confirmed by sequencing. A stop codon mutation was
introduced at amino acid position 3427 of exon 72 (numbered
according to Leiden muscular dystrophy pages DMD reference
sequence) [32] using single primer mutagenesis. This resulted in
the hE72-Luc(WT), hE72-Luc(TGA), hE72-Luc(TAG), and hE72-
Luc(TAA) constructs.
Additional reporter constructs were generated in the same way.
For hE40-Luc(WT), hE40-Luc(TGA), hE40-Luc(TAG), and hE40-
Luc(TAA), the 4 kb genomic segment spanning exon 39 to exon 41of
human DMD was amplified (forward:
59TTGATCCCATGGAA-
GACAATGAGGGTACTG
39 and reverse:
59GTAACCCATGG-
CAATTTGTGCAAAGTTGAG
39) and a stop codon introduced at
amino acid position 1891. In the case of mE23-Luc(WT) and mE23-
Luc(TAA), the 4 kb genomic segment spanning exon 22 to exon 24of
mouse Dmd (forward:
59CTTTCCCATGGTTTTTGACACTT-
TACCACC
39 and reverse:
59TACAACCATGGCTCTGCATTG-
TTTGAGCTG
39) was amplified, and a TAA stop codon introduced
into Dmd exon 23 at amino acid position 995, mimicking that of the
mdx mouse model [10].
Antisense Oligonucleotides
AONs with full phosphorothioate backbones and 29O-Methyl
RNA bases specific to the splice sites of human DMD exon 72, 40 and
50, and mouse Dmd exon 23 were purchased from Integrated DNA
Technologies. The following sequences were used: hE72+20+39
59UGAGUAUCAUCGUGUGAAAG
39; hE40+127+45
59UCCUU-
UCAUCUCUGGGCUC
39;h E 5 0 - 1 9 +8
59AACUUCCUCUUU-
AACAGAAAAGCAUAC
39;m E 2 3 +2-18
59GGCCAAACCUCGG-
CUUACCU
39.
Tissue Culture
HEK 293 cells were purchased from the American Type
Culture Collection (ATCC) and maintained at 37uC with 5% CO2
in DMEM (GibcoH) supplemented with 10% fetal bovine serum
(Hyclone) and 1X antibiotic-antimycotic (GibcoH). C2C12 cells
stably expressing a DMD hE50-GFP reporter construct (kindly
provided by Dr. Qi Long Lu of the Carolinas HealthCare System)
were maintained at 37uC with 5% CO2 in DMEM (GibcoH)
supplemented with 20% fetal bovine serum (Hyclone) and 1X
antibiotic-antimycotic (GibcoH). Conditionally immortal mdx cells
generated by intercrossing mdx and H-2K
b-tsA58 transgenic mice
[84] (kind gift from Dr. Qi Long Lu of the Carolinas Healthcare
System) were maintained in an undifferentiated myoblast state at
33uC with 5% CO2 in DMEM (GibcoH) supplemented with 20%
heat-inactivated fetal bovine serum (Hyclone), 2% L-glutamine
(GibcoH), 20 U/ml cIFN (Chemicon), 1% chick embryo extract
(US Biological) and 1X antibiotic-antimycotic (GibcoH).
RT-PCR Analysis of Exon Skipping
Spontaneous exon skipping was tested by transient transfection
of 1610
6 HEK 293 cells in a 9.6 cm
2 well of a 6-well plate
(Greiner) with 1 mg of hE72-Luc or hE40-Luc plasmid DNA and
3 ml of FuGene6 (Roche) as per manufacturer’s instructions. Total
RNA was extracted 48 h post-transfection using Qiagen RNeasy
mini kit columns and quantified using a NanoDrop 1000
spectrophotometer (Thermo Scientific). 200 ng RNA was used
as template for cDNA synthesis with random primers and
SuperScriptH II reverse transcriptase (Invitrogen), as per manu-
facturer’s instructions. 1 ml of the resulting cDNA was used as
template for each RT-PCR reaction of 35 cycles with PlatinumH
Taq DNA polymerase (Invitrogen). The primers used were the
same as the forward primers used to clone hE72-Luc and hE40-
Luc constructs, together with a reverse primer in luciferase (pGL2r:
59CTTTATGTTTTTGGCGTCTTCCA
39). PCR products were
visualized by the addition of SYBRH Gold (Invitrogen) to samples
prior to electrophoresis at 100 V through 2% agarose (Sigma)
dissolved in Tris-acetate-EDTA buffer (Sigma) and density of
bands quantified using Alpha Innotech’s AlphaEase FC
software, version 3.2.1.
HTS Transient Luciferase Reporter Gene Assays
HEK 293 cells were transiently transfected in bulk with the
DMD-Luciferase reporter gene construct, in the presence or absence
of a limiting concentration of AON (0.5 mM for hE40 and hE72,
and 0.2 mM for mE23). Transfection was achieved with a 3:1 ratio
of FuGene6 (Roche) in Opti-MEM media (Invitrogen), as per
manufacturer’s instructions, using 1 ng/well for hE72-Luc or
5 ng/well for hE40-Luc and mE23-Luc in 1536-well format, and
five times these amounts for 384-well format. Transfection mix
was diluted 1:5 with HEK cells at a density 320,000 cells/ml in
growth media lacking antibiotics.
For compound screens, 6 ml transfected cells (1920 cells) were
plated per well into 1536-well tissue culture-treated Greiner
custom white plates using GNF Systems on-line screening
equipment, incubated at 37uC with 5% CO2 for 24 h prior to
50 nl compound addition with a PinTool (GNF Systems) to a final
compound concentration of 8.3 mM (0.83% DMSO). Luciferase
activity was then measured 24 h post-compound addition (48 h
post-transfection) by the addition of 3 ml/well Bright-Glo (Pro-
mega) and a 60 second luminescence read with a Viewlux
TM CCD
Imager (Perkin Elmer).
MGC cDNA clones were screened by pre-spotting 40 ng/well
cDNA into Greiner white solid bottom 384-well tissue culture
plates, then addition of transfection mix containing the DMD-
Luciferase reporter gene construct +/2AON. HEK 293 cells were
then added (8000 cells/well) and cells maintained at 37uC with
5% CO2 prior to luciferase activity measurement 48 h post-
transfection.
The IDT kinome siRNA library was screened by bulk
transfection of the DMD-Luciferase reporter gene construct +/2
AONintoHEK 293cells 6 h earlier (transfected cells wereplatedin
175 cm
2 flasks (Greiner) at a density of 1.5610
6 cells/ml). Greiner
white solid bottom 384-well tissue culture plates pre-spotted with
14 ng siRNA/well had Lipofectamine RNAiMax (Invitrogen)
added in Opti-MEM media (Invitrogen), as per manufacturer’s
instructions. This transfection mix was diluted with DMD-Luciferase
transfected cells in growth media lacking antibiotics, to give
8000 cells/well and these cells were maintained at 37uC with 5%
CO2.Luciferaseactivitywasmeasured 72 h post-transfectionbythe
addition of Bright-Glo (Promega) and a 60 second luminescence
read with a Viewlux
TM CCD Imager (Perkin Elmer).
TaqMan qPCR Analysis
Relative amounts of exon skip and full-length transcripts were
quantified using total RNA extracted using Qiagen RNeasy 96 kits
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TMIII PlatinumH One-Step
qRT-PCR kits and an Applied Biosystems 7900HT fast real-time
PCR system. All TaqMan primers and FAM probes were obtained
from Integrated DNA Technologies, and VIC probes were
obtained from Applied Biosystems. In all cases standard curves
were generated for each 384-well TaqMan plate (Applied
Biosystems) using total RNA extracted from HEK 293 cells
transiently transfected with hE72-Luc or mE23-Luc constructs.
The same samples were used throughout each experiment,
allowing comparison of data between different plates.
DMD transcript levels were monitored following transient
transfection of HEK 293 cells with the hE72-Luc(TGA) minigene
reporter construct +/2 0.5 mM AON (40 ng/well reporter and
240,000 cells/well in 24-well Greiner plates), and co-transfection
of cDNA clones for 48 h (240 ng/well) or compound treatment for
24 h (0.5% DMSO added 6 h post-transfection), using primer-
probe sets specific to the splice junctions of DMD exon 71–73
(exon skip) (forward:
59 GTTACTCTGATCAACTTCTG
39, FAM
probe:
59 TTTTCCATTTCTGCTAGCGCAGAATCTACTG
39,
reverse:
59 CTATCATTTAGATAAGATCCATTG
39) and exon
72–73 (full-length) (forward:
59 CCTCGTCCCCTCAGCTTT-
C
39, FAM probe:
59 CACGATGATACTCATTCACGCATT-
GAACATTATG
39, reverse
59 CATTGCTGTTTTCCATTTC-
TGCTA
39). An initial denaturation step of 10 minutes at 95uC was
followed by cDNA synthesis at 52uC for 25 minutes, then products
amplified by 40 cycles of 15 seconds at 95uC and 1 minute at
60uC. Data from each primer-probe set was normalized to
expression levels of the h36B4 ribosomal protein housekeeping
gene for each sample (forward:
59CCACGCTGCTGAA-
CATGC
39, VIC probe:
59AACATCTCCCCCTTCTCCTTT-
GGGCT
39, reverse:
59TCGAACACCTGCTGGATGAC
39) and
results then expressed as the ratio of normalized skip/full-length
transcript levels.
Endogenous mouse Dmd exon skip and full-length transcript
levels were quantified following 48 h transfection of cDNA clones
or 24 h compound treatment (as described above) using mdx
myoblast cells +/2 0.2 mM AON and primer-probe sets spanning
Dmd splice junctions of exon 22–24 (exon skip) (forward:
59TCGGGAAATTACAGAATCACATAAAA
39, FAM probe:
59CCTTACAGAAATGGATGGCTGAAGTTGATGTTT
39, re-
verse:
59GCAGGCCATTCCTCTTTCAG
39) and exon 22–23
(full-length) (forward:
59GTTACTGAATATGAAATAATGGAG-
GAGAGA
39, FAM probe:
59TCGGGAAATTACAGGCTCTG-
CAAA
39, reverse:
59CCATTTTGTTGCTCTTTCAAAGAA
39). A
denaturation step of 10 minutes at 95uC was followed by cDNA
synthesis at 45uC for 40 minutes, then products amplified by 50
cycles of 15 seconds at 95uC and 1 minute at 60uC. Data was
normalized as described above.
High Content Imaging Mitotic Index Assay
HEK 293 cells were plated at a density of 8000 cells/well in
custom Greiner clear bottom black 384-well plates. Cells were
incubated at 37uC with 5% CO2 for 24 h prior to compound
addition in 12 point, 3-fold dilutions (highest final concentration
100 mM, 1% DMSO). 24 h post-compound addition cells were
fixed by submersion in ice-cold 100% methanol for 5 minutes and
stained using a method adapted from Rines et al. [85]. Fixative was
removed by washing in phosphate-buffered saline (PBS) (Sigma)
three times 5 minutes and cells were then incubated in 1.5% BSA/
PBS blocking solution for 2 h at room temperature. Blocking
solution was removed by washing in PBS three times 5 minutes
and antibodies specific for tubulin (1:1000 FITC conjugated -
Sigma) and phosphorylated histone H3 (1:100 Alexa647 conju-
gated - BD Biosciences) were added in PBS, together with 0.7 mg/
ml hoechst dye 33342 (Invitrogen), and left to incubate overnight
at 4uC. Antibodies were removed by washing in PBS three times 5
minutes and cells were imaged with a 10X/0.40 Olympus
UPlanSApo objective using an Opera
TM high content screening
system (Perkin Elmer). The percentage of mitotic cells (mitotic
index) was determined by identification of overlapping hoechst,
tubulin and phosphorylated histone H3 staining and normalized to
that of DMSO treated cells. Known tubulin modulators
nocodazole and taxol were included on each plate as positive
controls.
Alamar Blue Toxicity Assay
HEK 293 or mdx cells were plated in Greiner white solid bottom
384-well tissue culture plates in growth media (2000 cells/well in
50 ml) and maintained at 37uC with 5% CO2 prior to treatment
with 500 nl compound (1% DMSO) or transfected with cDNA
clones (as described above) for 48 h prior to addition of equal
volume of 1:5 dilution of alamarBlueH redox indicator (BioSour-
ce
TM) in growth media, to give a final dilution of 1:10. Cells were
maintained for 16–24 h at 37uC with 5% CO2 prior to reading
fluorescent signal on an Acquest plate reader (LJL Biosystems) using
1000 msintegrationtimewith530-25 nmexcitationand 580-10 nm
emission filters. Raw data (counts/second) was normalized to
DMSO treated cells and a known toxic compound (staurosporine)
was included as a positive control with each experiment.
FACS Analysis of Cell Cycle and Exon Skipping
C2C12 cells stably expressing an EGFP reporter construct
interrupted by DMD exon 50 (flanked by several hundred base
pairs of human DMD intronic sequence fused to chicken alpha actin
intronic sequence) [86] were plated at a density of 1610
6 cells/well
in Greiner 6-well plates in the presence of 0.5 mM hE50 AON
(transfected using a 3:1 FuGene 6 to AON ratio, as described
above). Compounds were added 6 h post-transfection in 8 point, 3-
folddilutions(highestfinalconcentration10 mM,0.5%DMSO)and
cells were harvested for FACS analysis 24 h later. In order to
preserve GFP signal, cells were fixed with 1X Mirsky’s Fixative
(National Diagnostics USA) rather than ethanol, and DNA stained
with10 mg/mlpropidiumiodide(Invitrogen).Data wascollectedon
a BD LSRII and analysis for percentage of cells expressing GFP,
and percentage of cells in G2/M phase of the cell cycle was
performed using FlowJo software. Nocodazole was included as a
positive control for induction of mitotic arrest.
Protein-Protein Interaction Analysis of cDNA Hits
The list of reconfirmed cDNA hits had all mouse genes converted
to their human orthologues, then gene ontology annotation was
used to classify proteins with known functions. Multiple human
protein-protein interaction databases, such as yeast-2-hybrid
databases (Hynet, http://www.prolexys.com) and other literature-
based protein-protein interaction databases (STRING, CORUM,
Bind, HPRD, MINT, Reactome),wereincorporated inthe network
analysis [87–89]. All interaction pairs were collected to form a
protein network. Protein networks were evaluated by 1000
permutation simulations and p-values were assigned. The core
components in the network were identified by MCODE analysis
[90] using Cytoscape V6.2 (http://www.cytoscape.org). Gene
Ontology (http://geneontology.org) enrichment analysis was char-
acterized by hypergeometric p-value, as described previously [91].
Supporting Information
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